Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention

DOI record: { "DOI": "10.1007/s13318-020-00640-6", "ISSN": [ "0378-7966", "2107-0180" ], "URL": "http://dx.doi.org/10.1007/s13318-020-00640-6", "alternative-id": [ "640" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 1, "value": "11 August 2020" }, { "group": { "label": "Declarations", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Funding", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "No funding source." }, { "group": { "label": "Conflict of interest", "name": "EthicsHeading" }, "name": "Ethics", "order": 3, "value": "The authors declare that they have no competing interest." }, { "group": { "label": "Ethics approval", "name": "EthicsHeading" }, "name": "Ethics", "order": 4, "value": "Not applicable." }, { "group": { "label": "Consent to participate", "name": "EthicsHeading" }, "name": "Ethics", "order": 5, "value": "Not applicable." }, { "group": { "label": "Consent for publication", "name": "EthicsHeading" }, "name": "Ethics", "order": 6, "value": "The authors have consent from their institutions." }, { "group": { "label": "Availability of data and material", "name": "EthicsHeading" }, "name": "Ethics", "order": 7, "value": "Not applicable." }, { "group": { "label": "Code availability", "name": "EthicsHeading" }, "name": "Ethics", "order": 8, "value": "Available at: ExternalRef removed." }, { "label": "Free to read", "name": "free", "value": "This content has been made available to all." } ], "author": [ { "affiliation": [], "family": "Tarek", "given": "Mohammad", "sequence": "first" }, { "ORCID": "http://orcid.org/0000-0003-0983-3693", "affiliation": [], "authenticated-orcid": false, "family": "Savarino", "given": "Andrea", "sequence": "additional" } ], "container-title": "European Journal of Drug Metabolism and Pharmacokinetics", "container-title-short": "Eur J Drug Metab Pharmacokinet", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2020, 8, 11 ] ], "date-time": "2020-08-11T14:07:32Z", "timestamp": 1597154852000 }, "deposited": { "date-parts": [ [ 2021, 8, 10 ] ], "date-time": "2021-08-10T23:19:13Z", "timestamp": 1628637553000 }, "indexed": { "date-parts": [ [ 2024, 4, 25 ] ], "date-time": "2024-04-25T15:08:50Z", "timestamp": 1714057730102 }, "is-referenced-by-count": 13, "issue": "6", "issued": { "date-parts": [ [ 2020, 8, 11 ] ] }, "journal-issue": { "issue": "6", "published-print": { "date-parts": [ [ 2020, 12 ] ] } }, "language": "en", "license": [ { "URL": "https://www.springer.com/tdm", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 8, 11 ] ], "date-time": "2020-08-11T00:00:00Z", "timestamp": 1597104000000 } }, { "URL": "https://www.springer.com/tdm", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 8, 11 ] ], "date-time": "2020-08-11T00:00:00Z", "timestamp": 1597104000000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1007/s13318-020-00640-6.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1007/s13318-020-00640-6/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1007/s13318-020-00640-6.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "page": "715-723", "prefix": "10.1007", "published": { "date-parts": [ [ 2020, 8, 11 ] ] }, "published-online": { "date-parts": [ [ 2020, 8, 11 ] ] }, "published-print": { "date-parts": [ [ 2020, 12 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "author": "WR Pötsch", "key": "640_CR1", "unstructured": "Pötsch WR, Fischer A, Müller W. Lexikon bedeutender Chemiker. New Delhi: Anamika Publishers & Distributors; 1988.", "volume-title": "Lexikon bedeutender Chemiker", "year": "1988" }, { "key": "640_CR2", "unstructured": "Wallace DJ, Hahn B, editors. Dubois’ lupus erythematosus. Philadelphia: Lippincott Williams & Wilkins; 2007.", "volume-title": "Dubois’ lupus erythematosus", "year": "2007" }, { "DOI": "10.1016/S1473-3099(03)00806-5", "author": "A Savarino", "doi-asserted-by": "publisher", "first-page": "722", "issue": "11", "journal-title": "Lancet Infect Dis", "key": "640_CR3", "unstructured": "Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):722–7.", "volume": "3", "year": "2003" }, { "DOI": "10.4155/fmc.13.113", "author": "KY Fong", "doi-asserted-by": "publisher", "first-page": "1437", "issue": "12", "journal-title": "Future Med Chem", "key": "640_CR4", "unstructured": "Fong KY, Wright DW. Hemozoin and antimalarial drug discovery. Future Med Chem. 2013;5(12):1437–50.", "volume": "5", "year": "2013" }, { "DOI": "10.1111/cts.12797", "author": "SLM Arnold", "doi-asserted-by": "publisher", "first-page": "642", "issue": "4", "journal-title": "Clin Transl Sci", "key": "640_CR5", "unstructured": "Arnold SLM, Buckner F. Hydroxychloroquine for treatment of SARS-CoV-2 infection? Improving our confidence in a model-based approach to dose selection. Clin Transl Sci. 2020;13(4):642–5. https://doi.org/10.1111/cts.12797.", "volume": "13", "year": "2020" }, { "DOI": "10.1016/j.ijantimicag.2020.105949", "author": "P Gautret", "doi-asserted-by": "publisher", "first-page": "105949", "journal-title": "Int J Antimicrob Agents", "key": "640_CR6", "unstructured": "Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honoré S. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;20:105949.", "volume": "20", "year": "2020" }, { "DOI": "10.1097/FTD.0000000000000261", "author": "S Morita", "doi-asserted-by": "publisher", "first-page": "259", "issue": "2", "journal-title": "Ther Drug Monit", "key": "640_CR7", "unstructured": "Morita S, Takahashi T, Yoshida Y, Yokota N. Population pharmacokinetics of hydroxychloroquine in Japanese patients with cutaneous or systemic lupus erythematosus. Ther Drug Monit. 2016;38(2):259–67.", "volume": "38", "year": "2016" }, { "DOI": "10.1007/s40262-020-00891-1", "author": "C Smit", "doi-asserted-by": "publisher", "first-page": "659", "issue": "6", "journal-title": "Clin Pharmacokinet", "key": "640_CR8", "unstructured": "Smit C, Peeters MYM, van den Anker JN, Knibbe CAJ. Chloroquine for SARS-CoV-2: implications of its unique pharmacokinetic and safety properties. Clin Pharmacokinet. 2020;59(6):659–69.", "volume": "59", "year": "2020" }, { "DOI": "10.1016/j.ijantimicag.2020.106078", "author": "TJ Oscanoa", "doi-asserted-by": "publisher", "first-page": "106078", "journal-title": "Int J Antimicrob Agents", "key": "640_CR9", "unstructured": "Oscanoa TJ, Romero-Ortuno R, Carvajal A, Savarino A. A pharmacological perspective of chloroquine in SARS-CoV-2 infection. Int J Antimicrob Agents. 2020;4:106078. https://doi.org/10.1016/j.ijantimicag.2020.106078.", "volume": "4", "year": "2020" }, { "DOI": "10.1128/aac.35.3.406", "author": "E Pussard", "doi-asserted-by": "publisher", "first-page": "406", "issue": "3", "journal-title": "Antimicrob Agents Chemother", "key": "640_CR10", "unstructured": "Pussard E, Lepers JP, Clavier F, et al. Efficacy of a loading dose of oral chloroquine in a 36-hour treatment schedule for uncomplicated plasmodium falciparum malaria. Antimicrob Agents Chemother. 1991;35(3):406–9. https://doi.org/10.1128/aac.35.3.406.", "volume": "35", "year": "1991" }, { "DOI": "10.1128/AAC.00339-08", "author": "HS Lim", "doi-asserted-by": "publisher", "first-page": "1468", "issue": "4", "journal-title": "Antimicrob Agents Chemother.", "key": "640_CR11", "unstructured": "Lim HS, Im JS, Cho JY, et al. Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother. 2009;53(4):1468–75. https://doi.org/10.1128/AAC.00339-08.", "volume": "53", "year": "2009" }, { "DOI": "10.1016/S1386-6532(00)00140-2", "author": "JR Boelaert", "doi-asserted-by": "publisher", "first-page": "137", "issue": "3", "journal-title": "J Clin Virol", "key": "640_CR12", "unstructured": "Boelaert JR, Piette J, Sperber K. The potential place of chloroquine in the treatment of HIV-1-infected patients. J Clin Virol. 2001;20(3):137–40.", "volume": "20", "year": "2001" }, { "DOI": "10.1097/00002030-200006160-00004", "author": "A Savarino", "doi-asserted-by": "publisher", "first-page": "1079", "issue": "9", "journal-title": "Aids", "key": "640_CR13", "unstructured": "Savarino A, Bottarel F, Malavasi F, Dianzani U. Role of CD38 in HIV-1 infection: an epiphenomenon of T-cell activation or an active player in virus/host interactions? Aids. 2000;14(9):1079–89.", "volume": "14", "year": "2000" }, { "DOI": "10.1084/jem.20051106", "author": "D Accapezzato", "doi-asserted-by": "publisher", "first-page": "817", "issue": "6", "journal-title": "J Exp Med", "key": "640_CR14", "unstructured": "Accapezzato D, Visco V, Francavilla V, et al. Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo. J Exp Med. 2005;202(6):817–28.", "volume": "202", "year": "2005" }, { "DOI": "10.1164/rccm.202003-0524LE", "author": "D Chang", "doi-asserted-by": "publisher", "first-page": "1150", "issue": "9", "journal-title": "Am J Respir Crit Care Med", "key": "640_CR15", "unstructured": "Chang D, Mo G, Yuan X, et al. Time kinetics of viral clearance and resolution of symptoms in novel coronavirus infection. Am J Respir Crit Care Med. 2020;201(9):1150–2", "volume": "201", "year": "2020" }, { "DOI": "10.1038/s41422-020-0282-0", "author": "M Wang", "doi-asserted-by": "publisher", "journal-title": "Cell Res", "key": "640_CR16", "unstructured": "Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020. https://doi.org/10.1038/s41422-020-0282-0.", "year": "2020" }, { "DOI": "10.1093/cid/ciaa237", "author": "X Yao", "doi-asserted-by": "publisher", "journal-title": "Clin Infect Dis", "key": "640_CR17", "unstructured": "Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa237.", "year": "2020" }, { "DOI": "10.1002/psp4.12543", "author": "A Gonçalves", "doi-asserted-by": "publisher", "journal-title": "CPT Pharmacometr Syst Pharmacol", "key": "640_CR18", "unstructured": "Gonçalves A, Bertrand J, Ke R, Comets E, de Lamballerie X, Malvy D, Pizzorno A, Terrier O, Rosa Calatrava M, Mentré F, Smith P. Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load. CPT Pharmacometr Syst Pharmacol. 2020. https://doi.org/10.1002/psp4.12543.", "year": "2020" }, { "DOI": "10.1073/pnas.1704011114", "author": "K Best", "doi-asserted-by": "publisher", "first-page": "8847", "issue": "33", "journal-title": "Proc Natl Acad Sci", "key": "640_CR19", "unstructured": "Best K, Guedj J, Madelain V, et al. Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies. Proc Natl Acad Sci. 2017;114(33):8847–52.", "volume": "114", "year": "2017" }, { "DOI": "10.1101/2020.02.29.965418", "author": "C Li", "doi-asserted-by": "publisher", "first-page": "2853", "journal-title": "Math Biosci Eng.", "key": "640_CR20", "unstructured": "Li C, Xu J, Liu J, et al. The within-host viral kinetics of SARS-CoV-2. Math Biosci Eng. 2020;17:2853–61. https://doi.org/10.1101/2020.02.29.965418.", "volume": "17", "year": "2020" }, { "DOI": "10.1101/2020.03.23.20040493", "author": "KS Kim", "doi-asserted-by": "publisher", "journal-title": "medRxiv.", "key": "640_CR21", "unstructured": "Kim KS, Ejima K, Ito Y, et al. Modelling SARS-CoV-2 dynamics: implications for therapy. medRxiv. 2020;. https://doi.org/10.1101/2020.03.23.20040493.", "year": "2020" }, { "DOI": "10.1371/journal.pcbi.1000533", "author": "L Rong", "doi-asserted-by": "publisher", "first-page": "e1000533", "issue": "10", "journal-title": "PLoS Comput Biol.", "key": "640_CR22", "unstructured": "Rong L, Perelson AS. Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol. 2009;5(10):e1000533. https://doi.org/10.1371/journal.pcbi.1000533.", "volume": "5", "year": "2009" }, { "DOI": "10.1371/journal.ppat.1002774", "author": "IL Shytaj", "doi-asserted-by": "publisher", "first-page": "e1002774", "issue": "6", "journal-title": "PLoS Pathog.", "key": "640_CR23", "unstructured": "Shytaj IL, Norelli S, Chirullo B, et al. A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathog. 2012;8(6):e1002774. https://doi.org/10.1371/journal.ppat.1002774.", "volume": "8", "year": "2012" }, { "DOI": "10.1128/JVI.01623-05", "author": "P Baccam", "doi-asserted-by": "publisher", "first-page": "7590", "issue": "15", "journal-title": "J Virol", "key": "640_CR24", "unstructured": "Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. Kinetics of influenza A virus infection in humans. J Virol. 2006;80(15):7590–9.", "volume": "80", "year": "2006" }, { "DOI": "10.1093/infdis/jis265", "author": "AS Perelson", "doi-asserted-by": "publisher", "first-page": "1642", "issue": "11", "journal-title": "J Infect Dis", "key": "640_CR25", "unstructured": "Perelson AS, Rong L, Hayden FG. Combination antiviral therapy for influenza: predictions from modeling of human infections. J Infect Dis. 2012;205(11):1642–5.", "volume": "205", "year": "2012" }, { "DOI": "10.1186/s13075-020-02211-1", "author": "H Carlsson", "doi-asserted-by": "publisher", "first-page": "1", "journal-title": "Arthritis Res Ther", "key": "640_CR26", "unstructured": "Carlsson H, Hjorton K, Abujrais S, Rönnblom L, Åkerfeldt T, Kultima K. Measurement of hydroxychloroquine in blood from SLE patients using LC-HRMS—evaluation of whole blood, plasma, and serum as sample matrices. Arthritis Res Ther. 2020;22:1–9.", "volume": "22", "year": "2020" }, { "DOI": "10.1517/13543776.16.9.1269", "author": "A Savarino", "doi-asserted-by": "publisher", "first-page": "1269", "issue": "9", "journal-title": "Expert Opin Ther Pat", "key": "640_CR27", "unstructured": "Savarino A, Buonavoglia C, Norelli S, Trani LD, Cassone A. Potential therapies for coronaviruses. Expert Opin Ther Pat. 2006;16(9):1269–88. https://doi.org/10.1517/13543776.16.9.1269.", "volume": "16", "year": "2006" }, { "DOI": "10.1038/s41592-019-0686-2", "author": "P Virtanen", "doi-asserted-by": "publisher", "first-page": "261", "issue": "3", "journal-title": "Nat Methods.", "key": "640_CR28", "unstructured": "Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, Burovski E, Peterson P, Weckesser W, Bright J. van der Walt SJ. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat Methods. 2020;17(3):261–72.", "volume": "17", "year": "2020" }, { "DOI": "10.1109/MCSE.2011.37", "author": "SV Walt", "doi-asserted-by": "publisher", "first-page": "22", "issue": "2", "journal-title": "Comput Sci Eng", "key": "640_CR29", "unstructured": "Walt SV, Colbert SC, Varoquaux G. The NumPy array: a structure for efficient numerical computation. Comput Sci Eng. 2011;13(2):22–30.", "volume": "13", "year": "2011" }, { "DOI": "10.1109/MCSE.2007.55", "author": "JD Hunter", "doi-asserted-by": "publisher", "first-page": "90", "issue": "3", "journal-title": "Comput Sci Eng", "key": "640_CR30", "unstructured": "Hunter JD. Matplotlib: a 2D graphics environment. Comput Sci Eng. 2007;9(3):90–5.", "volume": "9", "year": "2007" }, { "DOI": "10.1007/978-3-319-32726-6", "author": "HP Langtangen", "doi-asserted-by": "publisher", "key": "640_CR31", "unstructured": "Langtangen HP, Pedersen GK. Scaling of differential equations. Berlin: Springer Nature; 2016. https://doi.org/10.1007/978-3-319-32726-6.", "volume-title": "Scaling of differential equations", "year": "2016" }, { "DOI": "10.1093/cid/ciaa623", "author": "J Fan", "doi-asserted-by": "publisher", "journal-title": "Clin Infect Dis.", "key": "640_CR32", "unstructured": "Fan J, Zhang X, Liu J, et al. Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa623.", "year": "2020" }, { "DOI": "10.20944/preprints202005.0486.v1", "doi-asserted-by": "publisher", "key": "640_CR33", "unstructured": "Guérin V, Lévy P, Thomas JL, Lardenois T, Lacrosse P, Sarrazin E, de Andreis NR, Wonner M. Azithromycin and hydroxychloroquine accelerate recovery of outpatients with mild/moderate COVID-19. Preprints. 2020. https://doi.org/10.20944/preprints202005.0486.v1." }, { "DOI": "10.1002/cpt.1856", "author": "M Garcia-Cremades", "doi-asserted-by": "publisher", "journal-title": "Clin Pharmacol Ther", "key": "640_CR34", "unstructured": "Garcia-Cremades M, Solans BP, Hughes E, Ernest JP, Wallender E, Aweeka F, Luetkemeyer AF, Savic RM. Optimizing hydroxychloroquine dosing for patients with COVID-19: an integrative modeling approach for effective drug repurposing. Clin Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.1856.", "year": "2020" }, { "DOI": "10.1007/s40262-020-00891-1", "author": "C Smit", "doi-asserted-by": "publisher", "first-page": "1", "journal-title": "Clin Pharmacokinet", "key": "640_CR35", "unstructured": "Smit C, Peeters MY, van den Anker JN, Knibbe CA. Chloroquine for SARS-CoV-2: implications of its unique pharmacokinetic and safety properties. Clin Pharmacokinet. 2020;18:1. https://doi.org/10.1007/s40262-020-00891-1.", "volume": "18", "year": "2020" }, { "DOI": "10.3785/j.issn.1008-9292.2020.03.03", "doi-asserted-by": "publisher", "key": "640_CR36", "unstructured": "Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci). Published online March 6, 2020. https://doi.org/10.3785/j.issn.1008-9292.2020.03.03." }, { "DOI": "10.1093/jmcb/mjaa014", "author": "M Huang", "doi-asserted-by": "publisher", "first-page": "322", "issue": "4", "journal-title": "J Mol Cell Biol", "key": "640_CR37", "unstructured": "Huang M, Tang T, Pang P, Li M, Ma R, Lu J, Shu J, You Y, Chen B, Liang J, Hong Z. Treating COVID-19 with chloroquine. J Mol Cell Biol. 2020;12(4):322–5. https://doi.org/10.1093/jmcb/mjaa014.", "volume": "12", "year": "2020" }, { "DOI": "10.5582/bst.2020.01047", "author": "J Gao", "doi-asserted-by": "publisher", "journal-title": "Biosci Trends", "key": "640_CR38", "unstructured": "Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020. https://doi.org/10.5582/bst.2020.01047.", "year": "2020" }, { "DOI": "10.1101/2020.04.07.20056424", "doi-asserted-by": "publisher", "key": "640_CR39", "unstructured": "Borba MGS, Almeida Val F, Sampaio VS, et al. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). medRxiv. April 2020. https://doi.org/10.1101/2020.04.07.20056424." }, { "DOI": "10.1056/NEJMc2001737", "author": "L Zou", "doi-asserted-by": "publisher", "first-page": "1177", "issue": "12", "journal-title": "N Engl J Med", "key": "640_CR40", "unstructured": "Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, Guo Q. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177–9.", "volume": "382", "year": "2020" }, { "DOI": "10.1016/j.sapharm.2020.04.016", "author": "A Sarayani", "doi-asserted-by": "publisher", "journal-title": "Res Soc Adm Pharm", "key": "640_CR41", "unstructured": "Sarayani A, Cicali B, Henriksen CH, Brown JD. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. Res Soc Adm Pharm. 2020. https://doi.org/10.1016/j.sapharm.2020.04.016.", "year": "2020" }, { "key": "640_CR42", "unstructured": "Boulware D. Post-exposure prophylaxis/preemptive therapy for SARS-coronavirus-2 (COVID-19 PEP). Minneapolis: University of Minnesota. https://clinicaltrials.gov/ct2/show/NCT04308668. Accessed 27 Apr 2020." }, { "DOI": "10.1016/j.ijantimicag.2020.105988", "author": "SH Lee", "doi-asserted-by": "publisher", "first-page": "105988", "journal-title": "Int J Antimicrob Agents", "key": "640_CR43", "unstructured": "Lee SH, Son H, Peck KR. Can post-exposure prophylaxis for COVID-19 be considered as one of outbreak response strategies in long-term care hospitals? Int J Antimicrob Agents. 2020;17:105988. https://doi.org/10.1016/j.ijantimicag.2020.105988.", "volume": "17", "year": "2020" }, { "DOI": "10.1093/cid/ciaa320", "author": "P Pagliano", "doi-asserted-by": "publisher", "journal-title": "Clin Infect Dis", "key": "640_CR44", "unstructured": "Pagliano P, Piazza O, De Caro F, Ascione T, Filippelli A. Is hydroxychloroquine a possible postexposure prophylaxis drug to limit the transmission to healthcare workers exposed to coronavirus disease 2019? Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa320.", "year": "2020" }, { "DOI": "10.1016/S1473-3099(20)30296-6", "author": "N Principi", "doi-asserted-by": "publisher", "journal-title": "Lancet Infect Dis", "key": "640_CR45", "unstructured": "Principi N, Esposito S. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. Lancet Infect Dis. 2020. https://doi.org/10.1016/S1473-3099(20)30296-6.", "year": "2020" }, { "DOI": "10.1128/JVI.80.6.2684-2693.2006", "author": "YT Yen", "doi-asserted-by": "publisher", "first-page": "2684", "issue": "6", "journal-title": "J Virol", "key": "640_CR46", "unstructured": "Yen YT, Liao F, Hsiao CH, Kao CL, Chen YC, Wu-Hsieh BA. Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro. J Virol. 2006;80(6):2684–93.", "volume": "80", "year": "2006" }, { "DOI": "10.26434/chemrxiv.12488390.v1", "doi-asserted-by": "publisher", "key": "640_CR47", "unstructured": "Gil-Moles M, Basu U, Büssing R, Hoffmeister H, Türck S, Varchmin A, et al. Gold metallodrugs to fight the corona virus: inhibitory effects on the SpikeACE2 interaction and on PLpro protease activity by auranofin and gold organometallics. ChemRxiv. 2020. Preprint. https://doi.org/10.26434/chemrxiv.12488390.v1." }, { "DOI": "10.1186/1742-4690-10-71", "author": "IL Shytaj", "doi-asserted-by": "publisher", "first-page": "71", "issue": "1", "journal-title": "Retrovirology", "key": "640_CR48", "unstructured": "Shytaj IL, Chirullo B, Wagner W, Ferrari MG, Sgarbanti R, Della Corte A, LaBranche C, Lopalco L, Palamara AT, Montefiori D, Lewis MG. Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS. Retrovirology. 2013;10(1):71.", "volume": "10", "year": "2013" }, { "DOI": "10.1016/j.virol.2020.05.002", "author": "HA Rothan", "doi-asserted-by": "publisher", "journal-title": "Virology", "key": "640_CR49", "unstructured": "Rothan HA, Stone S, Natekar J, Kumari P, Arora K, Kumar M. The FDA-approved gold drug Auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells. Virology. 2020. https://doi.org/10.1016/j.virol.2020.05.002.", "year": "2020" } ], "reference-count": 49, "references-count": 49, "relation": { "has-preprint": [ { "asserted-by": "object", "id": "10.1101/2020.04.23.20076471", "id-type": "doi" } ] }, "resource": { "primary": { "URL": "https://link.springer.com/10.1007/s13318-020-00640-6" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "volume": "45" }